SCHEMBL5361865

SCHEMBL5361865

CC(C)(C)[SiH2]OC(C)(C)C1(c2ccccc2)CCN(C(=O)C(C)(C)c2ccc(Cl)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.42
CNR1 P21554 4/20 0.41
MC4R P32245 1/20 0.38
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38
APP P05067 1/20 0.37
CCR1 P32246 4/20 0.37
OPRD1 P41143 2/20 0.37
CYP3A4 P08684 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
EPHX2 P34913 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KMT2A Q03164 2/20 0.34
TET3 O43151 1/20 0.34
FBXL19 Q6PCT2 1/20 0.34
CXXC5 Q7LFL8 1/20 0.34
KDM2B Q8NHM5 1/20 0.34
CXXC4 Q9H2H0 1/20 0.34
KDM2A Q9Y2K7 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365659 0.82 HSD11B1 (0.53) HSD11B1SMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL5369330 0.79 SLC6A9 (0.38) CCR1OPRD1CYP3A4SMN1; SMN2KMT2A
SCHEMBL4703361 0.79 HSD11B1 (0.50) HSD11B1CNR1MC4RFNTAFNTB
SCHEMBL5362002 0.78 KDR (0.42) CYP3A4SMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL5366545 0.77 CCR3 (0.47) CNR1SMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL5362770 0.74 MEN1 (0.47) OPRD1SMN1; SMN2KMT2AMEN1OPRM1
SCHEMBL5369345 0.73 SLC6A2 (0.36) CCR1OPRD1CYP3A4SMN1; SMN2KMT2A
SCHEMBL4759002 0.72 HSD11B1 (0.53) HSD11B1CNR1MC4RFNTAFNTB
SCHEMBL5361858 0.71 CNR1 (0.47) HSD11B1CNR1MC4RFNTAFNTB
SCHEMBL5361856 0.71 CNR1 (0.42) HSD11B1CNR1MC4RFNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225331-A1 4,4-Disubstituted piperidines, and methods of use thereof SEPRACOR INC. (US) 2007-09-27 US disclosed
US-7217823-B2 4,4-Disubstituted piperidines, and methods of use thereof SEPRACOR INC. (US) 2007-05-15 US disclosed
US-20040142974-A1 4,4-disubstituted piperidines, and methods of use thereof HOEMANN MICHAEL Z (US) 2004-07-22 US disclosed
US-6656953-B2 Ligands for receptors such as dopamine, serotonin, or norepinephrine transporters; broad uses claimed, such as pain reliever and antidepressant SEPRACOR INC. 2003-12-02 US disclosed
US-20020177607-A1 4,4-Disubstitued piperidines, and methods of use thereof SEPRACOR INC. 2002-11-28 US disclosed
WO-2002046156-A2 4,4-DISUBSTITUTED PIPERIDINES FOR USE AS DOPAMINE, SEROTONIN AND NOREPINEPHRINE LIGANDS SEPRACOR, INC. (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177607-A1 4,4-Disubstitued piperidines, and methods of use thereof HTR2C, HTR5A, OPRL1 HSD11B1 1106/4885CNR1 138/4885MC4R 227/4885
US-20070225331-A1 4,4-Disubstituted piperidines, and methods of use thereof HTR5A, HTR2C, OPRL1 HSD11B1 1208/4885CNR1 121/4885MC4R 168/4885
US-20040142974-A1 4,4-disubstituted piperidines, and methods of use thereof HTR5A, HTR2C, OPRL1 HSD11B1 1208/4885CNR1 121/4885MC4R 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.